<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118505</url>
  </required_header>
  <id_info>
    <org_study_id>P16-03</org_study_id>
    <nct_id>NCT03118505</nct_id>
  </id_info>
  <brief_title>A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions</brief_title>
  <official_title>A Prospective, Randomized, Multi-Center, Open-Label Pilot Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain safety and effectiveness data on the investigational
      device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use
      in this indication. The study information may be used for a potential pivotal study design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological Fusion Success</measure>
    <time_frame>12 months</time_frame>
    <description>Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT);
No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and
Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Overall success is defined as the participant who meet the following five criteria:
Radiographic success, defined as radiological fusion success in the posterolateral space;
Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline;
Neurological success, defined as maintenance or improvement in neurological status;
No SAE related to the PLF grafting material or posterior fixation; and
No secondary surgeries classified as a &quot;failure.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>The self-administered Oswestry Disability Index (ODI) Questionnaire (Version 2.1) will be used to assess patient pain and ability to function. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>ODI success is defined as at least a 15-point improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Overall neurological success is defined as maintenance or improvement in four key neurological assessments: motor function, sensory function, reflexes, and straight leg raise. In order to be considered a success, each element in the motor, sensory, reflexes, and straight leg raise examinations must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back pain score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate back pain. The back pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back pain success at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Back pain success is defined as at least 30% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg pain score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate leg pain. The leg pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg pain success at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Leg pain success is defined as at least 30% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological fusion success rate at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT);
No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and
Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs related to the PLF grafting material or posterior fixation up to 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>A summary of AEs related to the PLF grafting material or posterior fixation up to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>A summary of secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Multi-Level Degenerative Lumbosacral Spinal Conditions</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infuse Bone Graft</intervention_name>
    <description>Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic DBM</intervention_name>
    <description>Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Degenerative lumbar spine condition:

               1. Requiring a PLF procedure using a bilateral metallic screw and rod system in 2-4
                  consecutive levels from L2-S1; and

               2. Diagnosed with: instability (up to and including Grade 2 spondylolisthesis,
                  retrolisthesis, or lateral listhesis), stenosis with documented pre-operative
                  instability, and/or recurrent disc herniation, any of which may have possible
                  concomitant lumbar degenerative deformity (Cobb angle ≤ 30 degrees).

          2. Preoperative ODI score ≥40.

          3. Preoperative pain score of ≥8 (out of 20) on the Preoperative Leg Pain Questionnaire.

          4. Most inferior treated spinal level is able to accommodate an interbody fusion device.

          5. ≥21 years of age at the time of signing the informed consent.

          6. Failed ≥6 months non-operative treatment (e.g., bed rest, physical therapy,
             medications, spinal injections, manipulation, and/or TENS).

          7. Is willing and able to comply with the study plan and able to understand and sign the
             Subject Informed Consent Form.

        Exclusion Criteria:

          1. Prior spinal fusion surgical procedure at the involved or adjacent spinal levels.
             (Prior non-fusion surgery at the target levels, including discectomy and/or
             single-level foraminotomy or laminectomy, is allowed.)

          2. Prior lumbar disc arthroplasty.

          3. Significant lumbar instability, defined as sagittal listhesis &gt;Grade 2 at any involved
             level using Meyerding's Classification or lateral listhesis &gt;25% lateral translation
             at any involved level.

          4. Planned use of an internal or external bone growth stimulator.

          5. Lumbar scoliosis &gt;30 degrees.

          6. Osteoporosis to a degree that spinal instrumentation is contraindicated or a history
             of atraumatic vertebral fracture.

          7. Morbidly obese, as defined by a Body Mass Index (BMI) &gt;40.

          8. Presence of active malignancy or prior history of malignancy.

          9. Overt or active bacterial infection, either local or systemic.

         10. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic,
             immunostimulating, or immunosuppressive agents within 30 days prior to implantation of
             the assigned treatment.

         11. Comorbidities precluding subject from being a surgical candidate.

         12. History of autoimmune disease known to affect bone metabolism or the spine (e.g.,
             spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease,
             Hashimoto's thyroiditis).

         13. History of any endocrine or metabolic disorder known to affect osteogenesis (e.g.,
             Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis
             imperfecta).

         14. History of exposure to any recombinant proteins used for bone formation (i.e., Infuse
             Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide
             Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft).

         15. Hypersensitivity or allergy to any components of the study treatments including, but
             not limited to, bone morphogenetic proteins (BMPs); injectable collagen; protein
             pharmaceuticals (e.g., monoclonal antibodies or gamma globulins); bovine collagen
             products; gentamicin or glycerol (which may be present in trace amounts in the DBM
             products); and/or instrumentation materials (titanium, titanium alloy, cobalt chrome,
             cobalt chrome alloy, or polyetheretherketone [PEEK]).

         16. History of any allergy resulting in anaphylaxis.

         17. Is a prisoner.

         18. Is mentally incompetent. If questionable, obtain psychiatric consult.

         19. Treatment with an investigational therapy (drug, device, and/or biologic) within 30
             days prior to implantation surgery, or such treatment is planned during the 24-month
             period following implantation of the study treatment.

         20. Pregnant or nursing. Females of child-bearing potential must agree not to become
             pregnant for one year following surgery.

         21. Any condition that would interfere with the subject's ability to comply with study
             instructions, might confound the interpretation of the study, or put the subject at
             risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Davis</last_name>
      <phone>916-734-1652</phone>
      <email>cjddavis@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Kee Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jared Ament, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Steadman Clinic</name>
      <address>
        <city>Vail</city>
        <state>Colorado</state>
        <zip>81657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitie Whitney</last_name>
      <phone>970-479-1587</phone>
      <email>kwhitney@thesteadmanclinic.com</email>
    </contact>
    <investigator>
      <last_name>Donald Corenman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehrich Bean, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Strauch, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thos Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Spine Health Institute</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Carrigan</last_name>
      <phone>407-303-2367</phone>
      <email>Pamela.Carrigan@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Chetan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuel King, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>AJ Piovesan, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation for Orthopedic Research and Education</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Warren, RN, CCRC</last_name>
      <phone>813-978-9700</phone>
      <phone_ext>6766</phone_ext>
      <email>dwarren@foreonline.org</email>
    </contact>
    <investigator>
      <last_name>John Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cruz Christian, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Growski, ARNP-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Glenney</last_name>
      <phone>404-778-6857</phone>
      <email>lauren.glenney@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Keith Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Gary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dheera Ananthakrishnan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Vinayek, M.Sc</last_name>
      <phone>317-715-5897</phone>
      <email>svinayek@indianaspinegroup.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Smucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Kraemer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Orthopedics</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kary S Stout, MBA, BS</last_name>
      <phone>260-436-8686</phone>
      <phone_ext>4278</phone_ext>
      <email>kstout@fwortho.com</email>
    </contact>
    <investigator>
      <last_name>Kevin A Rahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert M Shugart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Jianas</last_name>
      <phone>913-588-3252</phone>
      <email>ljianas@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Ashby</last_name>
      <phone>434-243-9508</phone>
      <email>CAA6M@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark E. Shaffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Po Yen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

